Product description

Clomicalm is a tablet for an effective treatment of canine separation anxiety as part of a behavioral management regimen.

Active ingredients

Each Clomicalm tablet contains:

Indications for use

• Separation Anxiety in dogs is not an expression of anger, it is a distress response characterized by:

  • Destruction
  • Soiling
  • Vocalization
  • Owner-seeking

• Clomicalm tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. Inappropriate barking or destructive behavior, as well as inappropriate elimination (urination or defecation) may be alleviated by the use of Clomicalm Tablets in conjunction with behavior modification.

• Separation anxiety is a complex behavior disorder displayed when the owner (or other attachment figure) leaves the dog. The signs of separation anxiety evaluated in controlled trials were vocalization, destructive behavior, excessive salivation, and inappropriate elimination. In the absence of the owner or attachment figure, dogs with separation anxiety may exhibit one or more of these clinical signs. Although the owner (attachment figure) may inadvertently misinterpret this behavior, which only happens in their absence, as spiteful, it is thought to be the result of anxiety experienced by the dog. Punishment is not considered appropriate for a dog with separation anxiety.

• Proper recognition of clinical signs, including a complete patient history and assessment of the patient’s household environment, is essential to accurately diagnose and treat separation anxiety.

• The use of Clomicalm should not replace appropriate behavioral and environmental management but should be used to facilitate a comprehensive behavior management program.

Administration and dosage

• The recommended daily dose of Clomicalm tablets is 2 to 4 mg/kg/day (0.9 -1.8 mg/lb/day) (see dosing table below). It can be administered as a single daily dose or divided twice daily based on patient response and/or tolerance of the side effects.
• It may be prudent to initiate treatment in divided doses to minimize side effects by permitting tolerance to side effects to develop or allowing the patient time to adapt if tolerance does not develop. To reduce the incidence of vomiting that may be experienced by some dogs, Clomicalm tablets may be given with a small amount of food.

• The specific methods of behavioral modification used in clinical trials involved desensitization and counterconditioning techniques. Since the manifestation of separation anxiety can vary according to the individual dog, it is advised that a specific behavior modification plan be developed based on a professional assessment of each individual case.

• Once the desired clinical effect is achieved and the owners have successfully instituted the appropriate behavioral modification, the dose of Clomicalm tablets may be reduced to maintain the desired effect or discontinued. Withdrawal side effects were not reported in studies with Clomicalm tablets in dogs. However, in clinical practice, it is recommended to taper the individual patient dose while continuing to monitor the dog’s behavior and clinical status through the dose reduction or withdrawal period. Continued behavioral modification is recommended to prevent recurrence of the clinical signs.

• The effectiveness and clinical safety of Clomicalm tablets for long-term use (i.e., for more than 12 weeks) has not been evaluated.

• Professional judgment should be used in monitoring the patient’s clinical status, response to therapy and tolerance to side effects to determine the need to continue treatment with Clomicalm tablets and to continue to rule-out physiological disorders which may complicate the diagnosis and treatment of separation anxiety.

Prescribing information